| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $10.5M | +4.9% | +21.5% |
| SG&A Expense | $6.4M | -5.0% | +3.0% |
| Operating Income | -$16.9M | -0.9% | -11.4% |
| Income Tax | $0 | — | — |
| Net Income | -$18.1M | -23.0% | +37.2% |
| EPS (Basic) | -$0.69 | -23.2% | +89.1% |
| EPS (Diluted) | -$0.69 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $12.2M | -43.3% | +16.8% |
| Current Assets | $18.2M | -44.2% | +4.5% |
| Total Assets | $52.7M | -23.1% | -8.7% |
| Current Liabilities | $12.0M | +20.4% | +32.7% |
| Total Liabilities | $44.6M | +1.5% | +6.8% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$36.6M | — | — |
| Capital Expenditures | $196K | — | — |
| Investing Cash Flow | -$184K | — | — |
| Financing Cash Flow | $721K | — | — |
| Free Cash Flow | -$36.8M | — | — |
| +89.1% |
| $8.1M |
| -67.1% |
| -49.2% |